Annual Research Review: The state of autism intervention science: progress, target psychological and biological mechanisms and future prospects
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background: There has been recent systematic review of key evidence in psychosocial intervention in autism but little review of biological treatments. Methods: We analyse the current literature from the perspective of intervention and mechanism targets across social and biological development. Results: The overall quality of trials evidence in autism intervention remains relatively low, despite some recent progress. Many treatments in common use have little or no evidence base. This is very concerning in such an important disorder. A variety of psychosocial interventions can show effect to improve some short‐term effects on children's immediate dyadic social interactions, for instance with caregivers. But showing true effectiveness in this developmental disorder requires generalisation of such effects into wider social contexts, on autism symptoms and in long‐term progress in development. Only a few interventions so far have begun to show this. A number of early phase interventions on biological targets have shown real promise, but none has yet progressed to larger scale effectiveness trials on behavioural or symptom outcomes. Conclusions: There has been enough progress in psychosocial intervention research now to be able to begin to identify some evidence‐based practice in autism treatment. To consolidate and improve outcomes, the next phase of intervention research needs improved trial design, and an iterative approach building on success. It may also include the testing of potential synergies between promising biological and psychosocial interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., Donaldson, A., & Varley, J. (2010) · Pediatrics · doi:10.1542/peds.2009-0958 · Cited by 2,835
Mediators and Moderators of Treatment Effects in Randomized Clinical Trials
Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.877 · Cited by 2,562
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome
Guy, J., Hendrich, B., Holmes, M., Martin, J. E., & Bird, A. (2001) · Nature Genetics · doi:10.1038/85899 · Cited by 1,558
Costs of Autism Spectrum Disorders in the United Kingdom and the United States
Buescher, A. V. S., Cidav, Z., Knapp, M., & Mandell, D. S. (2014) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2014.210 · Cited by 1,296
Convergence of genes and cellular pathways dysregulated in autism spectrum disorders
Pinto, D., Delaby, E., Merico, D., Barbosa, M., Merikangas, A., Klei, L., Thiruvahindrapuram, B., Xu, X., Ziman, R., Wang, Z., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.03.018 · Cited by 969
Self-citationGreen, J., Charman, T., McConachie, H., Aldred, C., Slonims, V., Howlin, P., Le Couteur, A., Leadbitter, K., Hudry, K., Byford, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60587-9 · Cited by 857 · cited 4×
“PACT was tested in an RCT of 152 children with core autism (age 2–5 years), which found large endpoint effect in optimising parental synchrony across three geographically varied contexts in the United Kingdom (Green et al., 2010; Pickles et al., 2016).”
InfluentialSelf-citationDawson, G., Jones, E. J. H., Merkle, K., Venema, K., Lowy, R., Faja, S., Kamara, D., Murias, M., Greenson, J., Winter, J., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.08.018 · Cited by 799 · cited 1×
“The results echo a previous study (Dawson et al., 2012), which studied EEG in 60% of the trial cases at endpoint only after two years intensive ESDM therapy.”
Oxytocin attenuates amygdala responses to emotional faces regardless of valence
Domes, G., Heinrichs, M., Gläscher, J., Büchel, C., Braus, D. F., & Herpertz, S. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.025 · Cited by 774 · cited 1×
“In a double-blind placebocontrol within-subject design, application of intranasal Oxytocin was associated with attenuated amygdala response to faces regardless of valence (Domes et al., 2007).”
Rogers, S. J., Estes, A., Lord, C., Vismara, L., Winter, J., Fitzpatrick, A., Guo, M., & Dawson, G. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.08.003 · Cited by 713 · cited 2×
“Techniques primarily using group or individual coaching and modelling techniques with parents do not show such reliable results (Carter et al., 2011; Rogers et al., 2012).”
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · cited 1×
“In a RCT of 15 adults with ASD, oxytocin was associated with significant reduction in repetitive behaviours in comparison to placebo (Hollander et al., 2003).”
Contribution of SHANK3 Mutations to Autism Spectrum Disorder
Moessner, R., Marshall, C. R., Sutcliffe, J. S., Skaug, J., Pinto, D., Vincent, J., Zwaigenbaum, L., Fernandez, B., Roberts, W., Szatmari, P., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/522590 · Cited by 681
Siller, M., & Sigman, M. (2002) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1014884404276 · Cited by 644 · cited 1×
“The concept of synchrony is allied to ‘responsiveness’ but derived more from the communication development literature, predicting communication and language outcomes in autism (Siller & Sigman, 2002) and usually measured using event-sampling rather than global rating.”
Language outcome in autism: randomized comparison of joint attention and play interventions
Kasari, C., Paparella, T., Freeman, S., & Jahromi, L. B. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.1.125 · Cited by 592
Long-Term Outcomes of Early Intervention in 6-Year-Old Children With Autism Spectrum Disorder
Estes, A., Munson, J., Rogers, S. J., Greenson, J., Winter, J., & Dawson, G. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.04.005 · Cited by 540 · cited 7×
“Causal treatment effect inference from these findings is limited however by the lack of intention to treat (ITT) analysis or adjustment for baseline pretreatment variables.”
InfluentialPickles, A., Le Couteur, A., Leadbitter, K., Salomone, E., Cole-Fletcher, R., Tobin, H., Gammer, I., Lowry, J., Vamvakas, G., Byford, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31229-6 · Cited by 519
Self-citationAldred, C., Green, J., & Adams, C. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00338.x · Cited by 449
Self-citationA randomized controlled trial of Hanen's ‘More Than Words’ in toddlers with early autism symptoms
Carter, A. S., Messinger, D. S., Stone, W. L., Celimli, S., Nahmias, A. S., & Yoder, P. (2011) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2011.02395.x · Cited by 446 · cited 1×
“Techniques primarily using group or individual coaching and modelling techniques with parents do not show such reliable results (Carter et al., 2011; Rogers et al., 2012).”
Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
Kasari, C., Kaiser, A., Goods, K., Nietfeld, J., Mathy, P., Landa, R., Murphy, S., & Almirall, D. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.019 · Cited by 415
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 3×
“…clinical trials, showed reduced anxiety, hyperarousal and attention in FXS patients in a small (n = 12) single-dose, single-arm open label study (Berry-Kravis et al., 2009), but no Phase II studies have been reported, probably due to CNS adverse effects with Fenobam use (Freidmann, Davis,…”
InfluentialBrain Serotonin and Dopamine Transporter Bindings in Adults With High-Functioning Autism
Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.137 · Cited by 352
Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349 · cited 2×
“The study found treatment effects on SRS social abilities confined to those with low baseline oxytocin levels (Parker et al., 2017).”
Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328 · cited 1×
“A double-blind RCT of GABAB agonist arbaclofen in 63 FXS patients aged 6–40 years found significant treatment effects in social behaviours and function (Berry-Kravis et al., 2012) but not on the primary endpoint measure of the Aberrant Behaviour Checklist-irritability subscale.”
Green, J., Pickles, A., Pasco, G., Bedford, R., Wan, M. W., Elsabbagh, M., Slonims, V., Gliga, T., Jones, E., Cheung, C., et al. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12728 · Cited by 328
Self-citationGuastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., Keating, C. M., Cacciotti‐Saija, C., & Einfeld, S. L. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12305 · Cited by 299 · cited 4×
“Outcome measurement in these studies – commonly the parent-rated Aberrant Behaviour Checklist (ABC; Aman, 1994), or the clinician-rated Global Improvement Scale (CGI; Leucht & Engel, 2006), Table 2 – have also been very different to that in psychosocial research, unfortunately limiting comparability.”
InfluentialLeigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 3×
“Clinical Global Impression Scale (CGI) but not on any behavioural measures (Leigh et al., 2013).”
InfluentialSiller, M., Hutman, T., & Sigman, M. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1584-y · Cited by 293
Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270
Wan, M. W., Green, J., Elsabbagh, M., Johnson, M., Charman, T., Plummer, F., & the BASIS Team (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12032 · Cited by 266
Self-citationNasal oxytocin for social deficits in childhood autism: A randomized controlled trial
Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1899-3 · Cited by 250 · cited 1×
“Dadds et al. (2014) evaluated oxytocin intervention in a double blind RCT in 38 children (age 7–16 years) with ASD administered during parent-child interaction training sessions over four consecutive days and found no treatment effect on social interactional skills or emotional recognition.”
Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., Brosset, P., Viellard, M., Bernoux, D., Rondeau, S., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.10 · Cited by 218 · cited 2×
“In a multi-centre phase 2 RCT (n- = 88, aged 2– 18 years), Bumetanide use was associated with significant improvement on parent and clinicianrated autism measures (Lemonnier et al., 2017); replication is awaited.”
Rahman, A., Divan, G., Hamdani, S. U., Vajaratkar, V., Taylor, C., Leadbitter, K., Aldred, C., Minhas, A., Cardozo, P., Emsley, R., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00388-0 · Cited by 203 · cited 3×
“DCMA Improved on video-aided intervention (Green et al., 2015; Rahman et al., 2016; Siller et al., 2013) Improved and mediates child initiation change on video-aided intervention (Green et al.”
Self-citationArbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9181-6 · Cited by 183
Bozdagi, O., Tavassoli, T., & Buxbaum, J. D. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-9 · Cited by 176
Serotonin and dopamine transporter binding in children with autism determined by SPECT
Makkonen, I., Riikonen, R., Kokki, H., Airaksinen, M. M., & Kuikka, J. T. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03027.x · Cited by 169
Jonsson, U., Alaie, I., Löfgren Wilteus, A., Zander, E., Marschik, P. B., Coghill, D., & Bölte, S. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12645 · Cited by 164 · cited 1×
“There are no appropriate assessments as yet of child and parent quality of life in autism, which could help look at wider outcome (Jonsson et al., 2017; McConachie et al., 2015).”
A trial of an iPad ™ intervention targeting social communication skills in children with autism
Fletcher-Watson, S., Petrou, A., Scott-Barrett, J., Dicks, P., Graham, C., O’Hare, A., Pain, H., & McConachie, H. (2016) · Autism · doi:10.1177/1362361315605624 · Cited by 160
A controlled trial of stimulant medication in children with the fragile X syndrome
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158 · cited 1×
“Dopamine Methylphenidate (Dopamine re-uptake inhibitor) (Hagerman et al., 1988), n = 15, double blind cross-over design FXS Parent & teacher behaviour checklists Improvement noted in attention, social skills and hyperactivity on methylphenidate Aripiprazole (partial D2 agonist) (Erickson, Early et al.”
Practitioner Review: Empirical evolution of youth psychotherapy toward transdiagnostic approaches
Marchette, L. K., & Weisz, J. R. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12747 · Cited by 156 · cited 1×
“…where we should be looking to focus on the common mechanisms across therapies that mediate treatment effect, and to combine evidenced effective treatment mechanisms into new implementation approaches combining modular aspects of intervention in clinically useful ways (Marchette & Weisz, 2017).”
Leucht, S., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300873 · Cited by 154 · cited 1×
“…measurement in these studies – commonly the parent-rated Aberrant Behaviour Checklist (ABC; Aman, 1994), or the clinician-rated Global Improvement Scale (CGI; Leucht & Engel, 2006), Table 2 – have also been very different to that in psychosocial research, unfortunately limiting comparability.”
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Wheeler, D. M., Silove, N., & Hazell, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub2 · Cited by 131
Kasari, C., Siller, M., Huynh, L. N., Shih, W., Swanson, M., Hellemann, G. S., & Sugar, C. A. (2014) · Infant Behavior and Development · doi:10.1016/j.infbeh.2014.08.007 · Cited by 127
Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTor
Oguro-Ando, A., Rosensweig, C., Herman, E., Nishimura, Y., Werling, D., Bill, B. R., Berg, J. M., Gao, F., Coppola, G., Abrahams, B. S., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.124 · Cited by 117 · cited 1×
“Rapamycin is a specific inhibitor of mTOR and in pre-clinical study has improved social behaviour in TSC (Sato et al., 2012), PTEN-related disorders (Zhou et al., 2009) and 15q11–13 duplication (Oguro-Ando et al., 2015).”
Electrocortical changes associated with minocycline treatment in fragile X syndrome
Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494105 · Cited by 108
Shire, S. Y., Chang, Y., Shih, W., Bracaglia, S., Kodjoe, M., & Kasari, C. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12672 · Cited by 104 · cited 3×
“Many studies demonstrating increased parental responsiveness have not found that this transmitted well into child effects; others have shown change in both parental responsiveness and child-initiated joint engagement joint attention (Shire et al., 2017).”
InfluentialEffect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study
Çaku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36750 · Cited by 77
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
Brief Report: Acamprosate in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67
Cited by
The contribution of environmental exposure to the etiology of autism spectrum disorder
Bölte, S., Girdler, S., & Marschik, P. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2988-4 · Cited by 509
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Rødgaard, E.-M., Jensen, K., Vergnes, J.-N., Soulières, I., & Mottron, L. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1956 · Cited by 185
Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis
Fraguas, D., Díaz-Caneja, C. M., Pina-Camacho, L., Moreno, C., Durán-Cutilla, M., Ayora, M., González-Vioque, E., de Matteis, M., Hendren, R. L., Arango, C., et al. (2019) · PEDIATRICS · doi:10.1542/peds.2018-3218 · Cited by 80
“Yet few treatments are efficacious for the core symptoms of autism, with only early and intensive treatments revealing improvements on dyadic and/or social interaction deficits.(3,4) Many patients with ASD and their relatives seek alternative medicine and nonmedicine treatment strategies.”
BackgroundCircuits for social learning: a unified model and application to autism spectrum disorder
DeMayo, M. M., Young, L. J., Hickie, I. B., Song, Y. J. C., & Guastella, A. J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.034 · Cited by 52
Metadata
- Authors
- Green, J., & Garg, S.
- Venue
- Journal of Child Psychology and Psychiatry
- Publisher
- Wiley
- Published
- 2018-03-25
- Volume
- 59
- Issue
- 4
- Pages
- 424-443
- ISSN
- 0021-9630 (ISSN-L)
- 1469-7610
- OpenAlex
- W2795399134
- Cited by
- 127
- References
- 50
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.